Oral DS107G in Moderate to Severe Atopic Dermatitis

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare the safety and efficacy of DS107G (2 g) to placebo in patients with moderate to severe atopic dermatitis.

DS107G capsules (2 g) will be orally administered for 8 weeks, and will be compared against placebo.

This study will enroll approximately 100 adult patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dignity Sciences Ltd.
• Treatments: Mineral Oil

Criteria

Inclusion Criteria:

• Male or female subject aged 18 years and older.

• Moderate to severe atopic dermatitis.

Exclusion Criteria:

• Clinically significant impairment of renal or hepatic function.

• History of hypersensitivity to any substance in DS107G or placebo capsules.

• Treatment with any experimental drug within 30 days prior to Day 0 visit (baseline).

• Excessive sun exposure, use of tanning booths or other ultraviolet (UV) light sources and/or is planning a trip to sunny climate.